20 (AIDX) EBITDA Margin (2025 - 2026)
20's (AIDX) quarterly EBITDA Margin came in at 408.45% in Q1 2026, down 26902.0% YoY from N/an in Q1 2025, and down 192.95% on a QoQ basis from 139.43% in Q1 2025.
20 (AIDX) EBITDA Margin (2025 - 2026) Analysis & Trends
20 (AIDX) has 2 years of EBITDA Margin data on file, last reported at 408.45% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.12 Bn | 193.52 Bn | 7.27 Bn | 13.44% |
| 2 | Stryker | 128.79 Bn | 125.32 Bn | 4.50 Bn | 25.18% |
| 3 | Medtronic | 119.30 Bn | 110.08 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 73.50 Bn | 72.96 Bn | 3.85 Bn | 21.65% |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.86 Bn | 1.35 Bn | 29.48% |
| 6 | Dexcom | 34.62 Bn | 32.67 Bn | 830.00 Mn | 24.33% |
| 7 | GE HealthCare Technologies | 34.05 Bn | 31.94 Bn | 2.18 Bn | 13.96% |
| 8 | Koninklijke Philips | 26.42 Bn | 23.10 Bn | 4.55 Bn | 10.30% |
| 9 | Steris | 23.15 Bn | 22.67 Bn | 684.20 Mn | 19.15% |
| 10 | 20 | 5.60 Mn | 1.05 Mn | 304,727.00 | -170.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.45% |
| Mar 31, 2025 | -139.43% |